Weiping Jia
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Shanghai 6th People's Hospital · Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Weiping Jia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:54 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT06921486 · The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · active not recruiting · Obesity and Overweight · principal investigator
- Ph2NCT06732960 · A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity PatientsShanghai Yinnuo Pharmaceutical Technology Co., Ltd. · completed · Overweight or Obesity · principal investigator
- Ph2/Ph3NCT04998032 · A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · completed · Type2 Diabetes · principal investigator
- Ph2NCT04314622 · A Study of Supaglutide in Chinese Type 2 Diabetes PatientsShanghai Yinnuo Pharmaceutical Technology Co., Ltd. · completed · Diabetes Mellitus, Type 2 · principal investigator
- N/ANCT03958838 · Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 CommunitiesShanghai 6th People's Hospital · completed · Type2 Diabetes, PreDiabetes · principal investigator
- N/ANCT03438617 · Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Extension & DisseminationShanghai 6th People's Hospital · completed · Type 2 Diabetes Mellitus · principal investigator
- N/ANCT03437525 · Peer Support in Diabetes Management - Insulin Peer SupportShanghai 6th People's Hospital · completed · Type 2 Diabetes Treated With Insulin · principal investigator
- Ph4NCT03344341 · A Phase IV Study in Drug-Naive Patients With T2DM in ChinaAstraZeneca · terminated · Type 2 Diabetes Mellitus · study chair
- Ph3NCT02477969 · Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Type 2 Diabetes Mellitus · principal investigator
- Ph4NCT02438397 · the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix InsulinShanghai 6th People's Hospital · unknown · Type 2 Diabetes · principal investigator
- N/ANCT02304250 · Dexamethasone and Wound Healing After Thyroid SurgeryQuanhong Zhou · completed · Wound Infection · study chair
- N/ANCT02225691 · Effect of Paired Testing to Poorly Controlled Chinese Diabetes on Glycemic Control and Self CareShanghai 6th People's Hospital · unknown · Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1 · principal investigator
- Ph3NCT02173457 · Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes PatientsChipscreen Biosciences, Ltd. · completed · Type 2 Diabetes · principal investigator
- Ph4NCT00736515 · Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 DiabetesServier (Tianjin) Pharmaceutical Co. LTD. · completed · Type 2 Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:54 UTC. The ranking covers the 200 most relevant of 183 PubMed records, and a shared surname and initials can bring in a namesake. All 183 on PubMed
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol · 20211,003 citationsRCR 54.5
- 694 citationsRCR 61.8
- 185 citationsRCR 7.3
- Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota.Nat Metab · 2024177 citationsRCR 26.8
- Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations.Cell Metab · 2023170 citationsRCR 16.9
- A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.J Clin Invest · 2020160 citationsRCR 8.2
- Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.Clin Cancer Res · 2020135 citationsRCR 4.9
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.Lancet Diabetes Endocrinol · 2014134 citationsRCR 4.7
- 130 citationsRCR 4.6
- Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.Clin Cancer Res · 2021127 citationsRCR 7.2